LON:BXP Beximco Pharmaceuticals (BXP) Share Price, News & Analysis → Massive Crisis Looming — Protect Your Savings Now (From Weiss Ratings) (Ad) Free BXP Stock Alerts GBX 37.66 -0.84 (-2.18%) (As of 06/14/2024 07:40 PM ET) Add Compare Share Share Today's Range 37.66▼ 38.5050-Day Range 36.08▼ 4152-Week Range 33.56▼ 45Volume17,750 shsAverage Volume60,714 shsMarket Capitalization£168.01 millionP/E Ratio470.75Dividend Yield7.97%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsStock AnalysisChartCompetitors Get Beximco Pharmaceuticals alerts: Email Address Ad Weiss RatingsMassive Crisis Looming — Protect Your Savings NowToday, Dr. Weiss is coming forward with a new warning, Only this time, it's not about the stock market, inflation, or recession … This time, it's about your financial freedom.Click here to learn how to prepare before it's too late. About Beximco Pharmaceuticals Stock (LON:BXP)Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.Read More BXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BXP Stock News HeadlinesFebruary 15, 2024 | lse.co.ukBeximco Pharma Share ChatDecember 14, 2023 | morningstar.comBeximco Pharmaceuticals Ltd DRNovember 4, 2023 | investing.comBeximco Pharmaceuticals Ltd. (BXPq)June 9, 2023 | finance.yahoo.comBXP.L - Beximco Pharmaceuticals LimitedMarch 12, 2023 | msn.comBeximco to produce medicines in Saudi Arabia from next yearFebruary 11, 2023 | fool.co.ukBeximco PharmaceuticalsOctober 26, 2022 | wsj.comBeximco Pharmaceuticals Ltd.September 8, 2022 | investing.comBeximco Pharmaceuticals Ltd (BXPH)January 20, 2022 | nasdaq.comBeximco Pharma Granted Sub-license To Produce Molupiravir - Quick FactsNovember 9, 2021 | nasdaq.comBeximco Pharma Launches Generic Molnupiravir In Bangladesh To Treat Symptomatic COVID-19August 2, 2021 | barrons.comBeximco Pharmaceuticals Ltd. GDRSee More Headlines Receive BXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beximco Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:BXP CUSIPN/A CIKN/A Webwww.beximco-pharma.com Phone+880-2-58611001FaxN/AEmployees5,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.08 Trailing P/E Ratio470.75 Forward P/E Ratio4.21 P/E GrowthN/ANet Income£5.33 billion Net Margins12.37% Pretax MarginN/A Return on Equity10.99% Return on Assets6.97% Debt Debt-to-Equity Ratio14.73 Current Ratio1.80 Quick Ratio0.37 Sales & Book Value Annual Sales£43.08 billion Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares446,110,000Free FloatN/AMarket Cap£168.01 million OptionableNot Optionable Beta0.63 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Mohammad Ali NawazChief Financial OfficerMr. S. M. Rabbur RezaChief Operating OfficerMr. Jamal Ahmed ChoudhuryDirector of Accounts & FinanceMr. Rizvi Ul KabirDirector of MarketingMr. M. A. Arshad BhuiyanGeneral Manager of Human ResourcesMr. Zakaria Seraj ChowdhuryHead of Distribution Services & Director of International MarketingMr. Mohammad Asad Ullah FCSCompany Secretary & Executive DirectorMore ExecutivesKey CompetitorsAmryt PharmaLON:AMYTBenchmarkLON:BMKAllergy TherapeuticsLON:AGYAlliance PharmaLON:APHAnimalcare GroupLON:ANCRView All Competitors BXP Stock Analysis - Frequently Asked Questions How have BXP shares performed in 2024? Beximco Pharmaceuticals' stock was trading at GBX 41.50 at the beginning of 2024. Since then, BXP stock has decreased by 9.3% and is now trading at GBX 37.66. View the best growth stocks for 2024 here. Is Beximco Pharmaceuticals a good dividend stock? Beximco Pharmaceuticals (LON:BXP) pays an annual dividend of GBX 3 per share and currently has a dividend yield of 6.21%. BXP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,750.00%. Payout ratios above 75% are not desirable because they may not be sustainable. How do I buy shares of Beximco Pharmaceuticals? Shares of BXP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:BXP) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.